M e l a n o m a    D i a g n o s t i c s

December 9, 2010: Dr. Kevin Scanlon, CEO, announces that Melanoma Diagnostics has licensed its technology to Myriad Genetics, Salt Lake City, Utah.

[Bullet] Download the official press release in Adobe PDF Format.

Other press releases:

  • Genome Web - Myriad Genetics Acquires Melanoma Technology genomeweb.com/dxpgx/myriad-genetics-acquires-melanoma-technology
  • Reuters - Suzannah Benjamin - Don Sebastian
  • Myriad Genetics Inc (MYGN.O) said it agreed to acquire the technology to diagnose skin cancer from Melanoma Diagnostics Inc.
  • Melanoma Diagnostics Sells Genetic Marker Technology? - socalTech.com
  • Myriad Acquires Novel Technology From Melanoma Diagnostics? - GlobeNewsWire
  • Myriad Takes Over Testing Platform from Melanoma Diagnostics? - Genetic Engineering News
  • Trading Markets (press release) - Zacks.com
  • Genetic Engineering News

[Bullet] More information on Dr. Scanlon's work can be found on kjscanlon.com.

Melanoma Diagnostics, Inc. is a molecular diagnostics company whose proprietary, patent-pending technology from the University of California San Francisco (UCSF) is unique for evaluating malignant melanoma (skin cancer). This novel technology includes a number of highly validated genetic markers, allowing it to discriminate between normal and melanoma (cancer) cells. The markers developed by Melanoma Diagnostics allow pathologists to discriminate between benign moles and melanoma, and to better characterize the risk of disease progression or metastasis.

Melanoma, a cancer of pigment-producing cells called melanocytes, most commonly occurs on the skin. Melanoma is caused by a combination of genetic predisposition and external factors such as ultraviolet exposure. Melanoma is the fifth most common cancer in males in the United States, and is the fastest growing cancer in terms of incidence. Each year in the US, 2.5-3 million moles are evaluated by biopsy, and of those over 100,000 are diagnosed as melanoma. All of these tumors biopsied for a potential diagnosis of melanoma can be evaluated significantly more accurately by our proprietary markers.

A Novel Product
  • First biomarker assay to distinguish between different categories of moles and melanomas (90% accuracy)
  • First prognostic products to outperform routine histological factors, predict risk of lymph node metastasis
  • Licensed technology developed and validated at UCSF
  • Platform technology to develop multi-marker assays
  • Developed proprietary antibodies that will be used exclusively in these diagnostic assays.
Current News

[Bullet] Our latest paper on "A multi-marker assay to distinguish malignant melanomas from benign
nevi" is available for download in Adobe PDF Format.

[Bullet] It is also available on the PNAS website at:
www.pnas.org/content/early/2009/03/27/0901185106.full.pdf+html.

[Bullet] Gene Screen Could Help Spot Melanoma
ABC News

[Bullet] New strategy developed to diagnose melanoma
University of California, San Francisco - News Office

[Bullet] Telling Moles From Melanomas Could Get Easier
Bloomberg.com

[Bullet] Gene Panel May Aid Melanoma Diagnosis
MedPage Today

[Bullet] YouTube
Dr. Kashani-Sabet, founding scientist, discusses melanoma diagnostics assay.

[Bullet] SciBX: Science-Business eXchange
Weekly publication that combines science and business.

[Bullet] Social Networks
Benign Nevus

[Benign Nevus] 		Malignant Melanoma

[Malignant Melanoma]

Home :: Executive Summary :: Clinical Studies :: FDA :: Management Team
Presentation :: Investors :: Links :: Contact Us
Baywalk Web Development :: Top of Page

        115,214 visitors